Vaxart Q2 Earnings Call Highlights
· finance.yahoo.com
Vaxart (OTCMKTS:VXRT) said it has reported positive 12-month safety data from the 400-participant Sentinel cohort of its Phase II-B COVID-19 vaccine trial and remains on track to disclose top-line data from the larger, approximately 5,000-participant main cohort in the first half of 2027. The compa
Among mRNA vaccine recipients, more than 60% reported injection-site pain, while 40.2% reported injection-site tenderness. Other reported side effects included ...